Document Detail


Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
MedLine Citation:
PMID:  19739235     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In this large-scale, retrospective study, the authors evaluated the diagnostic performances of computed tomography (CT), magnetic resonance (MR) imaging, and (18)F-fluorodeoxyglucose-positron emission tomography ((18)F-FDG-PET) in detecting hematogenous bone metastasis in patients with cervical cancer. The associated risk factors also were analyzed. METHODS: Patients with invasive cervical cancer who had both (18)F-FDG-PET studies and CT or MR imaging studies were selected. Patients who had either International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease or positive lymph node metastasis at the time of primary staging and patients who had suspected recurrent disease were included in the analyses. The diagnostic performances of PET was compared with the performance of CT and MR imaging by using the area under the receiver-operating-characteristic curve (AUC). Both univariate and multivariate analyses were applied to assess the risk factors for hematogenous bone metastasis at primary staging. RESULTS: PET was more sensitive than CT (P = .004) and was more specific than MR imaging (P = .04). The diagnostic performance of PET was significantly superior to the performance CT (AUC, 0.964 vs 0.662; P < .001) and MR (AUC, 0.966 vs 0.833; P = .033). Both FIGO stage and the extent of lymph node metastases were associated with hematogenous bone metastasis in univariate analysis. However, the extent of lymph node metastases was the only significant risk factor in multivariate analysis (P = .025). CONCLUSIONS: The current study demonstrated the superiority of (18)F-FDG-PET over CT and MR imaging for detecting hematogenous bone metastasis in patients with advanced cervical cancer. Hematogenous bone metastasis in cervical cancer was associated with the extent of lymph node metastases rather than with FIGO stage.
Authors:
Feng-Yuan Liu; Tzu-Chen Yen; Min-Yu Chen; Chyong-Huey Lai; Ting-Chang Chang; Hung-Hsueh Chou; Ji-Hong Hong; Yu-Ruei Chen; Koon-Kwan Ng
Related Documents :
17931795 - Fdg-pet/ct imaging for staging and target volume delineation in preoperative conformal ...
3497845 - Use of indium-111-labeled oc-125 monoclonal antibody in the detection of ovarian cancer.
19579015 - Accuracy of early and delayed fdg pet-ct and of contrast-enhanced ct in the evaluation ...
10565755 - Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical stagi...
1295875 - Magnetic resonance imaging of the saccular otolithic mass.
9682205 - The indirect use of ct numbers to establish material properties needed for monte carlo ...
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article    
Journal Detail:
Title:  Cancer     Volume:  115     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-25     Completed Date:  2010-01-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5470-80     Citation Subset:  AIM; IM    
Copyright Information:
(c) 2009 American Cancer Society.
Affiliation:
Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Bone Neoplasms / diagnosis*,  secondary*
Female
Fluorodeoxyglucose F18 / diagnostic use
Humans
Magnetic Resonance Imaging*
Middle Aged
Neoplastic Cells, Circulating
Positron-Emission Tomography*
Predictive Value of Tests
Retrospective Studies
Risk Factors
Sensitivity and Specificity
Tomography, X-Ray Computed*
Uterine Cervical Neoplasms / pathology
Chemical
Reg. No./Substance:
63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
Next Document:  Chronically inflamed livers up-regulate expression of inhibitory B7 family members.